Impact of growth hormone (GH) treatment on circulating Nt-proBNP concentrations and on cardiac function in adult GH-deficient patients

References

• Colao A, Marzullo P, Di Somma C, Lombardi G. Growth hormone and the heart. Clin Endocrinol (Oxf) 2001;54: 137–54.
   PubMed Web of Science ®Google Scholar
• Rosen T, Bengtsson BA. Premature mortality due to cardiovascular disease in hypopituitarism. Lancet 1990;336:285–8.
   PubMed Web of Science ®Google Scholar
• Bulow B, Hagmar L, Mikoczy Z, Nordstrom CH, Erfurth EM. Increased cerebrovascular mortality in patients with hypopituitarism. Clin Endocrinol (Oxf) 1997;46:75–81.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001;86:1874–81.
   PubMed Web of Science ®Google Scholar
• ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab 1999;84:2373–80.
   PubMed Web of Science ®Google Scholar
• Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 2003;108:2648–52.
   PubMed Web of Science ®Google Scholar
• Le Corvoisier P, Hittinger L, Chanson P, Montagne O, Macquin-Mavier I, Maison P. Cardiac effects of growth hormone treatment in chronic heart failure: a meta-analysis. J Clin Endocrinol Metab 2007;92:180–5.
   PubMedGoogle Scholar
• Cittadini A, Saldamarco L, Marra AM, Arcopinto M, Carlomagno G, Imbriaco M, Del FD, Vigorito C, Merola B, Oliviero U, Fazio S, Sacca L. Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction. J Clin Endocrinol Metab 2009;94:3329–36.
   PubMedGoogle Scholar
• Cenci MC, Soares DV, Spina LD, de Lima Oliveira Brasil RR, Lobo PM, Mansur VA, Gold J, Michmacher E, Vaisman M, Conceicao FL. Effects of 5 years of growth hormone (GH) replacement therapy on cardiac parameters and physical performance in adults with GH deficiency. Pituitary 2009;12:322–9.
   PubMedGoogle Scholar
• Palmeiro CR, Anand R, Dardi IK, Balasubramaniyam N, Schwarcz MD, Weiss IA. Growth hormone and the cardiovascular system. Cardiol Rev. Forthcoming 2012.
   Google Scholar
• Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998;339:321–8.
   PubMed Web of Science ®Google Scholar
• Pfister R, Schneider CA. Natriuretic peptides BNP and NT-pro-BNP: established laboratory markers in clinical practice or just perspectives? Clin Chim Acta 2004;349:25–38.
   PubMed Web of Science ®Google Scholar
• Troughton RW, Richards AM. B-type natriuretic peptides and echocardiographic measures of cardiac structure and function. JACC Cardiovasc Imaging 2009;2:216–25.
   PubMed Web of Science ®Google Scholar
• Berger R, Huelsman M, Strecker K, Bojic A, Moser P, Stanek B, Pacher R. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation 2002;105:2392–7.
   PubMed Web of Science ®Google Scholar
• Omland T, Persson A, Ng L, O’Brien R, Karlsson T, Herlitz J, Hartford M, Caidahl K. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 2002;106:2913–8.
   PubMed Web of Science ®Google Scholar
• Kragelund C, Gronning B, Kober L, Hildebrandt P, Steffensen R. N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med 2005;352:666–75.
   PubMed Web of Science ®Google Scholar
• Omland T, Sabatine MS, Jablonski KA, Rice MM, Hsia J, Wergeland R, Landaas S, Rouleau JL, Domanski MJ, Hall C, Pfeffer MA, Braunwald E. Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol 2007;50:205–14.
   PubMed Web of Science ®Google Scholar
• Di AE, Chowdhury R, Sarwar N, Ray KK, Gobin R, Saleheen D, Thompson A, Gudnason V, Sattar N, Danesh J. B-type natriuretic peptides and cardiovascular risk: systematic review and meta-analysis of 40 prospective studies. Circulation 2009;120:2177–87.
   PubMedGoogle Scholar
• Wang TJ, Larson MG, Levy D, Benjamin EJ, Leip EP, Omland T, Wolf PA, Vasan RS. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med 2004;350:655–63.
   PubMed Web of Science ®Google Scholar
• Rutten JH, Mattace-Raso FU, Steyerberg EW, Lindemans J, Hofman A, Wieberdink RG, Breteler MM, Witteman JC, van den Meiracker AH. Amino-terminal pro-B-type natriuretic peptide improves cardiovascular and cerebrovascular risk prediction in the population: the Rotterdam study. Hypertension 2010;55:785–91.
   PubMed Web of Science ®Google Scholar
• Patton KK, Ellinor PT, Heckbert SR, Christenson RH, DeFilippi C, Gottdiener JS, Kronmal RA. N-terminal pro-B-type natriuretic peptide is a major predictor of the development of atrial fibrillation: the Cardiovascular Health Study. Circulation 2009;120:1768–74.
   PubMed Web of Science ®Google Scholar
• Ekman B, Ohman PK, Arnqvist HJ, Lindstrom T, Nystrom FH. Individualized growth hormone substitution with normalized IGF-I levels does not stimulate the renin-angiotensin-aldosterone system. Clin Endocrinol (Oxf) 2002;57:473–9.
   PubMedGoogle Scholar
• Andreassen M, Faber J, Vestergaard H, Kistorp C, Kristensen LO. N-terminal pro-B-type natriuretic peptide in patients with growth hormone disturbances. Clin Endocrinol (Oxf) 2007;66:619–25.
   PubMedGoogle Scholar
• Johannsson G, Sverrisdottir YB, Ellegard L, Lundberg PA, Herlitz H. GH increases extracellular volume by stimulating sodium reabsorption in the distal nephron and preventing pressure natriuresis. J Clin Endocrinol Metab 2002;87: 1743–9.
   PubMed Web of Science ®Google Scholar
• Wallaschofski H, Saller B, Spilcke-Liss E, Lerch MM, Lohmann T, Eigenthaler M. Effects of growth hormone treatment on B-type natriuretic peptide as a marker of heart failure in adults with growth hormone deficiency. Horm Metab Res 2006;38:656–61.
   PubMedGoogle Scholar
• Lazurova I, Pura M, Wagnerova H, Tajtakova M, Sedlakova M, Tomas L, Payer J, Hruzikova P, Vanuga P, Podoba J, Trejbalova L, Popovic V, Koltowska-Haggstrom M. Effect of growth hormone replacement therapy on plasma brain natriuretic peptide concentration, cardiac morphology and function in adults with growth hormone deficiency. Exp Clin Endocrinol Diabetes 2010;118:172–6.
   PubMedGoogle Scholar
• Andreassen M, Faber J, Kjaer A, Petersen CL, Kristensen LO. Cardiac function in growth hormone deficient patients before and after 1 year with replacement therapy: a magnetic resonance imaging study. Pituitary 2011;14:1–10.
   PubMedGoogle Scholar
• Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ. Recommendations for chamber quantification: a report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18: 1440–63.
   PubMed Web of Science ®Google Scholar
• Januzzi JL, Jr., Camargo CA, Anwaruddin S, Baggish AL, Chen AA, Krauser DG, Tung R, Cameron R, Nagurney JT, Chae CU, Lloyd-Jones DM, Brown DF, Foran-Melanson S, Sluss PM, Lee-Lewandrowski E, Lewandrowski KB. The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol 2005;95: 948–54.
   PubMed Web of Science ®Google Scholar
• Van Beneden R, Gurne O, Selvais PL, Ahn SA, Robert AR, Ketelslegers JM, Pouleur HG, Rousseau MF. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 2004;10:490–5.
   PubMed Web of Science ®Google Scholar
• Brabant G, Wallaschofski H. Normal levels of serum IGF-I: determinants and validity of current reference ranges. Pituitary 2007;10:129–33.
   PubMed Web of Science ®Google Scholar
• Brabant G, von zur MA, Wuster C, Ranke MB, Kratzsch J, Kiess W, Ketelslegers JM, Wilhelmsen L, Hulthen L, Saller B, Mattsson A, Wilde J, Schemer R, Kann P. Serum insulin-like growth factor I reference values for an automated chemiluminescence immunoassay system: results from a multicenter study. Horm Res 2003;60:53–60.
   PubMed Web of Science ®Google Scholar
• Merola B, Cittadini A, Colao A, Longobardi S, Fazio S, Sabatini D, Sacca L, Lombardi G. Cardiac structural and functional abnormalities in adult patients with growth hormone deficiency. J Clin Endocrinol Metab 1993;77:1658–61.
   PubMed Web of Science ®Google Scholar
• Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation 2003;108:2648–52.
   PubMed Web of Science ®Google Scholar
• Isgaard J, Tivesten A, Friberg P, Bengtsson BA. The role of the GH/IGF-I axis for cardiac function and structure. Horm Metab Res 1999;31:50–4.
   PubMed Web of Science ®Google Scholar
• Colao A, Di Somma C, Cuocolo A, Spinelli L, Tedesco N, Pivonello R, Bonaduce D, Salvatore M, Lombardi G. Improved cardiovascular risk factors and cardiac performance after 12 months of growth hormone (GH) replacement in young adult patients with GH deficiency. J Clin Endocrinol Metab 2001;86:1874–81.
   PubMed Web of Science ®Google Scholar
• Climent VE, Pico A, Sogorb F, Aznar S, Lip GY, Marin F. Growth hormone therapy and the heart. Am J Cardiol 2006; 97:1097–102.
   PubMedGoogle Scholar
• Jin H, Yang R, Lu H, Ogasawara AK, Li W, Ryan A, Peale F, Paoni NF. Effects of early treatment with growth hormone on infarct size, survival, and cardiac gene expression after acute myocardial infarction. Growth Horm IGF Res 2002; 12:208–15.
   PubMed Web of Science ®Google Scholar
• Mulumba M, Cemeus C, Dumont L, du SP, Ong H, Marleau S. Recombinant bovine growth hormone-induced reduction of atrial natriuretic peptide is associated with improved left ventricular contractility and reverse remodeling in cardiomyopathic UM-X7.1 hamsters with congestive heart failure. Growth Horm IGF Res 2007;17:96–103.
   PubMedGoogle Scholar
• Verhelst J, Abs R. Long-term growth hormone replacement therapy in hypopituitary adults. Drugs 2002;62:2399–412.
   PubMedGoogle Scholar
• Ho KY, Kelly JJ. Role of growth hormone in fluid homeostasis. Horm Res 1991;36(Suppl. 1):44–8.
   PubMedGoogle Scholar
• Moller J, Nielsen S, Hansen TK. Growth hormone and fluid retention. Horm Res 1999;51(Suppl. 3):116–20.
   PubMedGoogle Scholar
• Alexopoulou O, Beguin C, De NP, Maiter D. Clinical and hormonal characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients. Eur J Endocrinol 2004;150:1–8.
   PubMed Web of Science ®Google Scholar
• Hogenhuis J, Voors AA, Jaarsma T, Hillege HL, Boomsma F, van Veldhuisen DJ. Influence of age on natriuretic peptides in patients with chronic heart failure: a comparison between ANP/NT-ANP and BNP/NT-proBNP. Eur J Heart Fail 2005;7:81–6.
   PubMed Web of Science ®Google Scholar
• Loke I, Squire IB, Davies JE, Ng LL. Reference ranges for natriuretic peptides for diagnostic use are dependent on age, gender and heart rate. Eur J Heart Fail 2003;5:599–606.
   PubMed Web of Science ®Google Scholar
• Emdin M, Passino C, Del Ry S, Prontera C, Galetta F, Clerico A. Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. Clin Chem Lab Med 2003;41:686–92.
   PubMed Web of Science ®Google Scholar
• Mehra MR, Uber PA, Park MH, Scott RL, Ventura HO, Harris BC, Frohlich ED. Obesity and suppressed B-type natriuretic peptide levels in heart failure. J Am Coll Cardiol 2004;43:1590–5.
   PubMed Web of Science ®Google Scholar